Pro Share Advisors LLC Rigel Pharmaceuticals Inc Transaction History

Pro Share Advisors LLC

$39.7 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$1.12 - $1.57 $2,711 - $3,800	2,421 Added 8.55%	30,746 $45,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.56 $4,385 - $9,501	6,091 Added 27.39%	28,325 $41,000
Q3 2023 Nov 13, 2023	SELL	$1.07 - $1.39 $24 - $31	-23 Reduced 0.1%	22,234 $24,000
Q2 2023 Aug 10, 2023	BUY	$1.12 - $1.82 $2,180 - $3,543	1,947 Added 9.59%	22,257 $28,000
Q1 2023 May 11, 2023	SELL	$1.25 - $2.0 $2,368 - $3,790	-1,895 Reduced 8.53%	20,310 $26,000
Q4 2022 Feb 02, 2023	SELL	$0.67 - $11.9 $7,607 - $135,112	-11,354 Reduced 33.83%	22,205 $33,000
Q3 2022 Nov 04, 2022	BUY	$1.1 - $12.2 $851 - $9,442	774 Added 2.36%	33,559 $40,000
Q2 2022 Aug 01, 2022	SELL	$0.67 - $3.19 $11,353 - $54,057	-16,946 Reduced 34.08%	32,785 $37,000
Q1 2022 May 10, 2022	SELL	$2.22 - $3.45 $25,925 - $40,289	-11,678 Reduced 19.02%	49,731 $149,000
Q4 2021 Feb 08, 2022	BUY	$2.36 - $3.57 $7,122 - $10,774	3,018 Added 5.17%	61,409 $163,000
Q3 2021 Nov 12, 2021	SELL	$3.5 - $4.5 $57,785 - $74,295	-16,510 Reduced 22.04%	58,391 $212,000
Q2 2021 Aug 13, 2021	BUY	$3.09 - $4.54 $19,065 - $28,011	6,170 Added 8.98%	74,901 $325,000
Q1 2021 May 14, 2021	BUY	$3.35 - $4.93 $16,763 - $24,669	5,004 Added 7.85%	68,731 $235,000
Q4 2020 Feb 09, 2021	BUY	$2.35 - $3.74 $36,829 - $58,613	15,672 Added 32.61%	63,727 $223,000
Q3 2020 Nov 13, 2020	SELL	$1.78 - $4.13 $3,511 - $8,148	-1,973 Reduced 3.94%	48,055 $115,000
Q2 2020 Aug 03, 2020	BUY	$1.41 - $2.05 $24,140 - $35,098	17,121 Added 52.03%	50,028 $92,000
Q1 2020 May 15, 2020	SELL	$1.27 - $3.0 $33,202 - $78,432	-26,144 Reduced 44.27%	32,907 $51,000
Q4 2019 Feb 12, 2020	SELL	$1.6 - $2.43 $8,772 - $13,323	-5,483 Reduced 8.5%	59,051 $126,000
Q3 2019 Nov 12, 2019	SELL	$1.63 - $2.62 $3,333 - $5,357	-2,045 Reduced 3.07%	64,534 $121,000
Q2 2019 Aug 13, 2019	SELL	$2.02 - $2.61 $17,095 - $22,088	-8,463 Reduced 11.28%	66,579 $174,000
Q1 2019 May 15, 2019	BUY	$2.0 - $2.65 $1,736 - $2,300	868 Added 1.17%	75,042 $193,000
Q4 2018 Feb 14, 2019	SELL	$2.08 - $3.36 $29,617 - $47,843	-14,239 Reduced 16.11%	74,174 $171,000
Q3 2018 Nov 14, 2018	SELL	$2.6 - $3.59 $5,369 - $7,413	-2,065 Reduced 2.28%	88,413 $284,000
Q2 2018 Aug 13, 2018	BUY	$2.83 - $4.11 $10,864 - $15,778	3,839 Added 4.43%	90,478 $256,000
Q1 2018 May 14, 2018	SELL	$3.54 - $4.54 $50,409 - $64,649	-14,240 Reduced 14.12%	86,639 $307,000
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $71,647 - $95,382	22,182 Added 28.19%	100,879 $391,000
Q3 2017 Nov 13, 2017	BUY	$2.18 - $2.57 $10,743 - $12,664	4,928 Added 6.68%	78,697 $200,000
Q2 2017 Aug 11, 2017	BUY	N/A	73,769	73,769 $201,000

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account